A Phase 2 clinical trial of Harbour BioMed‘s investigational therapy batoclimab, also known as HBM9161, for myasthenia…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
NMD Pharma is launching a Phase 1/2a trial in the Netherlands to evaluate for the first time NMD670, an…
3P Biopharmaceuticals and Toleranzia are continuing their partnership to develop Toleranzia’s potential therapy candidate, TOL2, for people living with…
Younger age, more advanced thymoma (tumors of the thymus) and cancer recurrence predict poorer survival in people with…
Harbour BioMed‘s HBM9161 was found to be safe and effective at reducing the levels of autoimmune disease-associated antibodies in…
Treatment with Rituxan (rituximab) benefits patients with myasthenia gravis (MG) with either anti-acetylcholine receptor (AChR) or muscle-specific tyrosine kinases…
A 35 year-old man with myasthenia gravis (MG) who developed a rare lymphoma — called mucosa-associated lymphoid tissue…
Cyclophosphamide, a medicine with immunosuppressant abilities, may be a potential short-term alternative treatment for refractory — or difficult to treat…
First Clinical Trial of CAR-T Therapy for Myasthenia Gravis, Descartes-08, Enrolling at Miami Site
A first clinical trial of Descartes-08, a CAR T-cell therapy for people with generalized myasthenia gravis (GMG) by …
UCB will add the investigational candidate zilucoplan to its therapeutic pipeline for the treatment of people with myasthenia…